The predictive value of hypometabolism in focal epilepsy: a prospective study in surgical candidates

PURPOSE

FDG PET is an established tool in presurgical epilepsy evaluation, but it is most often used selectively in patients with discordant MRI and EEG results. Interpretation is complicated by the presence of remote or multiple areas of hypometabolism, which leads to doubt as to the true location of the seizure onset zone (SOZ) and might have implications for predicting the surgical outcome. In the current study, we determined the sensitivity and specificity of PET localization prospectively in a consecutive unselected cohort of patients with focal epilepsy undergoing in-depth presurgical evaluation.

METHODS

A total of 130 patients who underwent PET imaging between 2006 and 2015 matched our inclusion criteria, and of these, 86 were operated on (72% with a favourable surgical outcome, Engel class I). Areas of focal hypometabolism were identified using statistical parametric mapping and concordance with MRI, EEG and intracranial EEG was evaluated. In the surgically treated patients, postsurgical outcome was used as the gold standard for correctness of localization (minimum follow-up 12 months).

RESULTS

PET sensitivity and specificity were both 95% in 86 patients with temporal lobe epilepsy (TLE) and 80% and 95%, respectively, in 44 patients with extratemporal epilepsy (ETLE). Significant extratemporal hypometabolism was observed in 17 TLE patients (20%). Temporal hypometabolism was observed in eight ETLE patients (18%). Among the 86 surgically treated patients, 26 (30%) had hypometabolism extending beyond the SOZ. The presence of unilobar hypometabolism, included in the resection, was predictive of complete seizure control (p = 0.007), with an odds ratio of 5.4.

CONCLUSION

Additional hypometabolic areas were found in one of five of this group of nonselected patients with focal epilepsy, including patients with "simple" lesional epilepsy, and this finding should prompt further in-depth evaluation of the correlation between EEG findings, semiology and PET. Hypometabolism confined to the epileptogenic zone as defined by EEG and MRI is associated with a favourable postoperative outcome in both TLE and ETLE patients.

Absolute Luminescence Efficiency of Europium-Doped Calcium Fluoride (CaF2:Eu) Single Crystals under X-ray Excitation

The absolute luminescence efficiency (AE) of a calcium fluoride (CaF2:Eu) single crystal doped with europium was studied using X-ray energies met in general radiography. A CaF2:Eu single crystal with dimensions of 10 × 10 × 10 mm3 was irradiated by X-rays. The emission light photon intensity of the CaF2:Eu sample was evaluated by measuring AE within the X-ray range from 50 to 130 kV. The results of this work were compared with data obtained under similar conditions for the commercially employed medical imaging modalities, Bi4Ge3O12 and Lu2SiO5:Ce single crystals. The compatibility of the light emitted by the CaF2:Eu crystal, with the sensitivity of optical sensors, was also examined. The AE of the 10 × 10 × 10 mm3 CaF2:Eu crystal peaked in the range from 70 to 90 kV (22.22 efficiency units; E.U). The light emitted from CaF2:Eu is compatible with photocathodes, charge coupled devices (CCD), and silicon photomultipliers, which are used as radiation sensors in medical imaging systems. Considering the AE results in the examined energies, as well as the spectral compatibility with various photodetectors, a CaF2:Eu single crystal could be considered for radiographic applications, including the detection of charged particles and soft gamma rays.

High resolution BrainPET combined with simultaneous MRI

After the successful clinical introduction of PET/CT, a novel hybrid imaging technology combining PET with the versatile attributes of MRI is emerging. At the Forschungszentrum Jülich, one of four prototypes available worldwide combining a commercial 3T MRI with a newly developed BrainPET insert has been installed, allowing simultaneous data acquisition with PET and MRI. The BrainPET is equipped with LSO crystals of 2.5 mm width and Avalanche photodiodes (APD) as readout electronics. Here we report on some performance characteristics obtained by phantom studies and also on the initial BrainPET studies on various patients as compared with a conventional HR+ PET-only scanner. Material, methods: The radiotracers [18F]-fluoroethyl- tyrosine (FET), [11C]-flumazenil and [18F]-FP-CIT were applied. Results: Comparing komthe PET data obtained with the BrainPET to those of the HR+ scanner demonstrated the high image quality and the superior resolution capability of the BrainPET. Furthermore, it is shown that various MR images of excellent quality could be acquired simultaneously with BrainPET scans without any relevant artefacts. Discussion, conclusion: Initial experiences with the hybrid MRI/BrainPET indicate a promising basis for further developments of this unique technique allowing simultaneous PET imaging combined with both anatomical and functional MRI.

Cerebral arterial inflow assessment with 18F-FDG PET: methodology and feasibility

Positron emission tomography (PET) with 18fluorodeoxyglucose (18F-FDG) is increasingly used in neurology. The measurement of cerebral arterial inflow (QA) using 18F-FDG complements the information provided by standard brain PET imaging. Here, injections were performed after the beginning of dynamic acquisitions and the time to arrival (t0) of activity in the gantry's field of view was computed. We performed a phantom study using a branched tube (internal diameter: 4mm) and a 18F-FDG solution injected at 240 mL/min. Data processing consisted of (i) reconstruction of the first 3s after t0, (ii) vascular signal enhancement and (iii) clustering. This method was then applied in four subjects. We measured the volumes of the tubes or vascular trees and calculated the corresponding flows. In the phantom, the flow was calculated to be 244.2 mL/min. In each subject, our QA value was compared with that obtained by quantitative cine-phase contrast magnetic resonance imaging; the mean QA value of 581.4±217.5 mL/min calculated with 18F-FDG PET was consistent with the mean value of 593.3±205.8 mL/min calculated with quantitative cine-phase contrast magnetic resonance imaging. Our 18F-FDG PET method constitutes a novel, fully automatic means of measuring QA.

Structure-Function-Based Quantitative Brain Image Analysis

Many neurodegenerative dementias produce significant alterations in the brain that are often not detectable by neurologic tests or with structural imaging. PET is ideally suited for monitoring cell/molecular events early in the course of a disease as well as during pharmacologic therapy. During the past 2 decades, molecular neuroimaging using PET and magnetic resonance (MR) has advanced elegantly and steadily gained importance in the clinical and research arenas. Software- and hardware-based multimodality brain imaging allowing the correlation between anatomic and molecular information has revolutionized clinical diagnosis and now offers unique capabilities for the clinical neuroimaging community and neuroscience researchers at large.